作者: Samuel Aballéa , Aurélie Millier , Sébastien Bineau , Mondher Toumi , Jürgen Rehm
DOI: 10.1159/000362408
关键词:
摘要: BACKGROUND: Alcohol consumption is one of the most important factors for disease and disability in Europe. In clinical trials, nalmefene has resulted a significant reduction number heavy-drinking days (HDDs) per month total alcohol (TAC) among alcohol-dependent patients versus placebo. METHODS: A microsimulation model was developed to estimate alcohol-attributable diseases injuries with dependence explore relevance reducing consumption. RESULTS: For all considered, events (inpatient episodes) increased HDDs TAC year. The predicted that 20 year would result 941 fewer 100,000 patients, while intake 3,000 g/year pure (ethanol) 1,325 patients. CONCLUSION: potential gains were considerable. © 2014 S. Karger AG, Basel. Language: en